Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04704219 |
|---|---|
| Brief Title: | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61) |
| First Submitted : | January 7, 2021 |
| First Submitted that Met QC Criteria : | January 7, 2021 |
| First Posted : | January 11, 2021 |
| Last Update Submitted that Met QC Criteria : | January 12, 2024 |
| Last Update Posted : | January 16, 2024 |